A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Status:
Recruiting
Trial end date:
2026-11-13
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug selpercatinib is safe and more
effective compared to a standard treatment in participants with rearranged during
transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or
has spread to other parts of the body. Participants who are assigned to the standard
treatment and discontinue due to progressive disease have the option to potentially crossover
to selpercatinib.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company Loxo Oncology, Inc.
Collaborators:
Eli Lilly and Company Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company